Please assess the completion status of the following clinical trial:

Trial Title: Relapse Rate in Hepatitis C Patients Treated With Peginterferon Alfa-2b Plus Ribavirin in Common Clinical Practice in France (P05484)(Completed)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* The patient must demonstrate his/her continued willingness to participate in the study.~* The patient must be at least 18 years of age, of either gender.~* Patients with chronic hepatitis C (any genotype) who received Peg-IFN alfa-2b + Ribavirin as first treatment for hepatitis C.~* Negative HCV-RNA at the end of treatment (24 or 48 weeks according to the product labeling as appropriate), measured by the assay used at each institution. Only institutions using an assay with a limit of detection of 50 IU/mL or less will be eligible.~Exclusion Criteria:~* Patients who completed treatment with PegInterferon Alfa-2b plus Ribavirin more than 4 weeks before study entry.~* Patients with positive HCV-RNA at the end of treatment (24 or 48 weeks according to the product labeling as appropriate).~* Patients treated for a period shorter than the enrollment period.~* Patients co-infected with human immunodeficiency virus (HIV).~* Patients co-infected with hepatitis B virus (HBV).~* Patients who do not use appropriate effective method of birth control after the end of treatment (according to legal recommendations).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Peg-IFN alfa-2b + ribavirin (Type: None): Participants with chronic hepatitis C (CHC) treated with Peg-IFN alfa-2b + ribavirin as first treatment, in common clinical practice, who had negative hepatitis-C virus (HCV)-ribonucleic acid (RNA) by the end of treatment (24 or 48 weeks per product labeling).

Based on this trial design, predict the completion outcome and termination type (if applicable).